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ABSTRAK 
 
Latar belakang 
Ethambutol merupakan antara rawatan utama bagi penyakit tuberkulosis. Walau 
bagaimanapun ubat ini berpotensi untuk menyebabkan kemerosotan fungsi 
penglihatan yang kekal. Kajian ini adalah untuk menunjukkan perbandingan di antara 
parameter anatomi dan fungsi penglihatan dengan menggunakan kaedah fungsi saraf 
optik secara konvensional dan dengan mengukur ketebalan lapisan gentian saraf 
retina serta corak potensi rangsangan saraf sebelum dan selepas rawatan kepada 
pesakit tuberkulosis yang di rawati menggunakan regim yang mengandungi 
ethambutol. 
 
 
Kaedah 
Ini ialah kajian prospektif yang melibatkan 72 biji mata seramai 36 orang pesakit 
yang telah dirawat dengan ethambutol melalui strategi Pemerhatian Langsung 
Rawatan Jangka Pendek di Hospital Universiti Sains Malaysia, Kelantan, Malaysia. 
Kadar ketepatan penglihatan, fungsi saraf optik, keluasan medan penglihatan, 
analisis lapisan gentian saraf retina (RNFL) menggunakan topografi kohoren optik 
(OCT) serta corak potensi rangsangan saraf (PVEP) telah dinilai. Pemeriksaan telah 
dijalankan sebelum terapi dimulakan serta pada tempoh 3 bulan setelah rawatan 
dimulakan. 
 
 
 
viii 
 
Keputusan 
Analisis keluasan medan penglihatan pada parameter purata lencongan (md) 
menunjukkan perubahan yang signifikan secara statistik (p=0.010). Terdapat juga 
perubahan yang signifikan pada OCT dan PVEP. Perbandingan ketebalan pada 
RNFL menunjukkan peningkatan ketebalan pada semua kuadran (p<0.05) dan 
kelewatan pada puncak pendam P100 serta pengurangan amplitud dalam penilaian 
PVEP (p<0.001). Tiada perbezaan antara kadar ketepatan penglihatan, kadar 
penglihatan warna, kadar pengamatan cahaya, kadar ketepuan warna merah serta 
keadaan fundus sebelum dan selepas rawatan dengan ethambutol. 
 
 
Kesimpulan 
Penggunaan OCT untuk mengesan ketebalan RNFL dan PVEP untuk mengukur 
amplitud serta kelewatan P100 boleh membantu dalam pengesanan perubahan pada 
struktur anatomi serta fungsi saraf optik lebih awal berbanding ujian fungsi saraf 
secara konvensional semasa di peringkat subklinikal. Perubahan ini mungkin 
disebabkan oleh keracunan ethambutol pada peringkat awal dan ini mementingkan 
penggunaan OCT dan PVEP penting bagi pemantauan pesakit tuberkulosis. 
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Abstract 
 
Introduction 
Ethambutol is a first line drug for the treatment of tuberculosis. However this drug 
has caused incidences of irreversible ocular toxicity. This study is to compare the 
anatomical and visual function using conventional optic nerve function tests, 
measurement of retinal nerve fibre layer and pattern visual evoked potential changes 
in patients with tuberculosis treated with a regime containing ethambutol. 
 
 
Method  
This is a prospective study involving 72 eyes of 36 patients treated with ethambutol 
according to the Directly Observed Treatment Short Course (DOTS) strategy in 
Hospital Universiti Sains Malaysia, Kelantan, Malaysia. The optic nerve function, 
retinal nerve fibre layer (RNFL) on optical coherence topography (OCT) and pattern 
visual evoked potential (PVEP) were assessed. The examination was performed 
before the start of therapy and three months after.   
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Results  
Visual field analysis of mean deviation (md) showed significant statistical change 
(p=0.010). There were also significant changes on OCT and PVEP. Comparison of 
RNFL thickness showed an increased thickness in all quadrants (p<0.05) and a 
delayed P100 peak latency and decreased amplitude on PVEP assessment (p<0.001). 
There was no change in visual acuity, colour vision, light brightness, red saturation 
and fundus findings pre and post ethambutol. 
 
Conclusion  
The use of OCT to detect RNFL thickness and PVEP to assess P100 latency and 
amplitude can assist in the detection of subclinical anatomical and visual function 
changes prior to conventional optic nerve function tests. These changes may 
represent early ethambutol related optic neuropathy, making OCT and PVEP 
important tools in monitoring tuberculosis patients. 
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Introduction
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INTRODUCTION 
 
Tuberculosis is an endemic disease, especially in developing countries like Malaysia. 
It is caused by Mycobacterium tuberculosis, which can infect any part of the body, 
but mainly infects the lungs.  
 
Ethambutol hydrochloride is commonly used for the treatment of tuberculosis and  
Mycobacterium avium complex infections. Its exact mechanism of action is 
unknown; however the drug acts as a chelating agent by disrupting one of the several 
metal-containing enzymes in the nucleic acid structure of mycobacteria. 
 
Ethambutol has been used as a first line drug in the treatment of tuberculosis, along 
with other drugs. It has been proven effective in combating Mycobacterium 
tuberculosis. However there is a drawback, as there is evidence that ethambutol 
causes toxic optic neuropathy. 
 
The normal daily dose is 15mg/kg/day, which is also practiced in Hospital Universiti 
Sains Malaysia. Studies have shown that there is no safe dose for ethambutol. There 
have been recorded cases of ethambutol toxicity in cases where a lower dosage of the 
drug was used. There have been reports of toxicity occurring as early as immediately 
or one month after treatment. Thus it has become a practice for treating physicians to 
refer these patients to ophthalmologists prior to starting the drugs to obtain baseline 
ocular findings. This ensures that the future changes related to ethambutol toxicity 
can be detected. 
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Early detection of the disease may help in diagnosing and preventing occurrence of 
severe toxic optic neuropathy in the early stages of toxicity. The common practice is 
to examine and assess the optic nerve functions which include the vision, relative 
afferent pupillary defect, colour vision, red desaturation, light brightness and visual 
field changes. 
 
Optical coherence topography (OCT) of the retinal nerve fibre layer (RNFL) and 
electrophysiological tests have the potential to document subtle anatomical and 
functional changes. OCT is an instrument that is used to measure the retinal 
thickness and its layers. It has now become an important tool to view the cross-
sectional image of the microstructure of the retina. It is commonly used to measure 
the nerve fibre layer in glaucoma patients by accessing the optic disc parameters and 
also the RNFL to detect thinning of the normal retinal layers around the optic disc. 
 
 The OCT could prove to be a useful tool to detect early changes in RNFL thickness 
in patients post ethambutol treatment. However, studies regarding RNFL changes in 
ethambutol treatment have given varied results. These changes have been suggested 
to be attributed to ethambutol toxicity. The postulation is that ethambutol causes 
toxicity similar to alcohol induced toxicity. Ethambutol is derived from butanol. 
Ethambutol produces the metabolite ethylenediiminodibutyric acid, which is possibly 
involved in the transformation of metal ions to chelating agents. This leads to the 
chelation of copper ions within the optic nerve axons, causing decreased levels of 
copper. Due to this process, a disruption in axonal transport occurs. The disruption of 
axonal transport is suspected to cause energy depletion and axonal swelling in the 
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early stages. After the initial swelling, there is papilomacular-bundle-nerve necrosis, 
which leads to further neuronal-cell death, which manifests as thinning of the RNFL. 
These findings suggest that OCT of RNFL can detect early anatomical changes 
possibly due to ethambutol toxicity, which are not visible in a normal routine eye 
examination. 
 
Visual Evoked Potential (VEP) is an electrophysiological test that records visually 
evoked electrophysiological signals extracted from the electroencephalograhic 
activity in the visual cortex recorded from the overlying scalp. As the visual cortex is 
activated primarily by the central visual field, VEP depends on the functional 
integrity of central vision at any level of the visual pathway including the eye, retina, 
optic nerve, optic radiations and occipital cortex. VEP may be able to detect anterior 
visual conduction disturbances and functional changes prior to gross neuro-
ophthalmic examination abnormalities. 
 
There are two methods of measuring VEP, depending on the patient’s vision. Flash 
VEP is used for patients with poor vision who cannot focus on the “X” checkerboard 
stimulus. Pattern VEP is used on patients with good vision and who can focus on the 
stimulus. It also has greater sensitivity and accuracy. 
 
VEP may be abnormal in patients with no visual pathway defect, such as amblyopia, 
uncorrected refractive error, media opacity and inattention or lethargy. Thus a 
complete examination and correction of refractive error has to be done prior to the 
test. 
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P100 is the most consistent and least variable peak. Delayed P100 peak latency and 
decreased amplitude are expected in cases with meningitis, optic neuritis or 
neuropathy, demyelination, anoxia, stroke and other possibilities of diseases that 
affect the retina, optic nerve or brain. 
 
This study aims to evaluate the changes in optic nerve function, RNFL and pattern 
VEP pre and 3 months post treatment with ethambutol in tuberculosis patients. We 
postulate that these changes may be due to ethambutol ocular toxicity. We recruited 
patients with normal optic nerve function, OCT and VEP pre ethambutol, and 
assessed them again three months post treatment to look for changes in RNFL on 
OCT and VEP P100 latency and amplitude. We also assessed optic nerve function 
via conventional tests. We hope to discover whether OCT and VEP can detect 
changes that may signify subclinical optic nerve dysfunction in ethambutol 
treatment. 
 
 
  
 
Chapter 2 
Study 
Protocol 
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INTRODUCTION 
 
2.1 OVERVIEW OF ETHAMBUTOL USAGE AND TOXICITY 
Ethambutol hydrochloride is commonly used for the treatment of tuberculosis (TB) 
and Mycobacterium avium complex infections. Its exact mechanism is unknown; 
however the drug acts as a chelating agent by disrupting one of the several metal-
containing enzymes in the nucleic acid structure of mycobacteria.1 
 
Ethambutol is an effective drug in the first line treatment for tuberculosis. However 
its use has been associated with the incidences of ocular toxicity2-3. The incidence of 
ocular related ethambutol toxicity was noted to be from 1% to 18% from various 
studies.4-5 
 
The most hazardous ocular side effect of this drug is toxic optic neuropathy which is 
dependent on the dose and duration of treatment. It has been reported that ethambutol 
results in bilateral optic neuropathy and includes both central and peripheral types.6 
 
Characteristics of ocular toxicity of ethambutol 
Classically the ocular toxicity is described as dose-related and duration-related, 
 
Dose-related 
There has been no reported ‘safe-dose’ of ethambutol.7-8  Furthermore there have 
been no conclusive evidence correlating the severity of the neuritis of the optic nerve 
with the total intake of ethambutol.9 
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The usual daily dose is 15mg/kg/day10-11 (that is also the routine dose in Hospital 
Universiti Sains Malaysia (HUSM)), though there have been cases of reported 
toxicity observed at doses as low as 12.3mg/kg per day.12 
 
Duration-related 
It has been reported that the mean interval between onset of therapy and the toxic 
effects is around 3 to 5 months.7,12-13 On the other hand an article has noted quite a 
high prevalence of toxicity at 1 to 2 months of treatment and there is a report of 
immediate toxicity following ethambutol treatment.12 
 
Reversibility 
There are studies which found that patients who experience ethambutol toxicity often 
have severe and persistent visual defects, despite the fact that they have received the 
appropriate dosages and are monitored regularly for visual acuity and colour vision 
with prompt discontinuation of the drug, with the slightest sign of toxicity9,14. 
 
However, not all the patients who had described visual acuity improvement after the 
discontinuation of the drug had complete recovery. An example of this would be the 
study conducted by Tsai and Lee’s 14, where 50% of the patients sustained permanent 
visual impairment without recovery.12,15 
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Monitoring and preventive measures 
There are several international guidelines which have been published suggesting 
measures used for the prevention and early detection of ethambutol-induced ocular 
toxicity. 16-20 
 
Despite regular follow-ups and optic nerve function tests performed on all patients 
on ethambutol with the recommended dosage, there are still those who develop 
ethambutol toxicity. This makes it difficult to believe the norm of regular optic nerve 
function tests, which includes visual acuity, visual field, colour vision test, light 
brightness and red desaturation which has been used to detect ocular toxicity is 
actually effective in clinical practice. 
 
Early detection of ocular toxic effects before occurrence of symptoms is of great 
value to prevent extensive optic nerve damage and furthermore allow the complete 
recovery of normal function.21 
 
The VEP has proven very useful in detecting anterior visual conduction disturbances 
where there are little disturbances in the neuro-ophthalmological examination.22-25 
 
Yiannikas8, Van Lith26 and Melamud27 found that VEP may be considerably 
disturbed at a stage when there is little neuro-ophthalmologic examination 
abnormality. 
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An essential practice during routine eye follow-ups for patients on ethambutol 
therapy is to assess their optic nerve function while they are on the medication and 6 
months post cessation of ethambutol. 
 
Optic nerve functions consist of relative afferent pupillary defect examination, colour 
vision, red desaturation, light brightness and visual field. Relative afferent pupillary 
defect is examined in a dark room using a bright torch. Patients are instructed to look 
at a distance and not at the torch. The torch is swung from one eye to the other and 
the pupil is observed to note the constriction of the pupil size. 
 
Colour vision is assessed using Ishihara plates which detect red-green colour defects. 
The plates consist of a number of coloured plates that have randomised dots which 
differ in colour and size. These patterns of dots form a number or shape clearly 
visible to subjects with normal colour vision but invisible or difficult to see for 
subjects who have red-green colour vision defect. There are certain plates that can 
produce or transform a figure that can only be seen by colour deficient individuals. 
The scoring depends on the number of plates that the patient is able to interpret 
correctly. 
 
Red desaturation and light brightness is done by subjectively asking the patient to 
compare a bright red object and a bright torch light separately by accessing one eye 
at a time. Generally red desaturation is examined first then light brightness. The 
patient has to compare if the red colour hue and light brightness is the same in either 
eye or reduced in one compared to the other. The extent of deficiency is amounted in 
percentage.  
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Visual field is recorded using the Humphrey Visual Field. The desired field is 24-2. 
This machine assesses one eye at a time, 24 degrees of the patient’s field of view is 
tested by instructing the patient to focus on a centre point in the dome of the 
Humphrey Visual Field while flashing lights will appear randomly around. If the 
patient is able to see the flashing lights without moving his/her eye, the patient is 
required to press a button which is given to him/her. A printout of the patient’s result 
will be used to interpret if there is any visual field loss. Patients with optic 
neuropathy usually will present with enlarged blind spots or paracentral scotomas. 
 
RNFL thickness is accessed using OCT. Each eye is tested one at a time. The patient 
is asked to look straight at a green light in the machine without blinking or moving 
and measurements of the optic nerve head parameters are taken and analysed by the 
OCT machine. The RNFL thickness is measured in the peripapillary region 
surrounding the optic disc. It is divided into four quadrants namely the superior, 
inferior, temporal and nasal quadrant. The average retinal nerve fibre is measured 
using spectralis OCT (Hyun JS et al, 2011) Average thickness 106.38 um, superior 
125.00 um, inferior 132.46 um, temporal 91.04 um, nasal 78.50 um. 
 
OCT 
OCT has now become an important tool to view the cross-sectional image of the 
microstructure of the retina. It is commonly used to measure the nerve fibre layer in 
glaucoma patients 28. The OCT could prove to be a useful tool to detect early 
changes in RNFL in patients post ethambutol treatment. In a study that was 
performed by Samantha J Chai et al. and Zoumalan CI et al., their results showed 
that there was a decrease in the RNFL thickness especially in the temporal quadrant 
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in patients who developed ethambutol induced optic neuropathy.29-30 However there 
was one study done by Jae Keun Chung et al that found an increase in average retinal 
nerve fibre thickness.31  
 
In this study we expect to find a decreased retinal nerve fibre thickness especially in 
the temporal quadrant of the optic nerve head.  
 
In 1991, Huang et al32 reported the OCT, was used as a non- invasive ocular imaging 
tomography. It uses a coloured representation of the tissue structures, based on the 
intensity of the returned light. OCT has been used to measure the retinal nerve fibre 
thickness of the optic nerve head and macula. It has been used to measure and 
monitor the retinal nerve fibre thickness in glaucoma and macula diseases patients. 
OCT uses light to measure micrometer axial resolution. 
 
OCT uses a low coherence inferometry as its basic principle, where the light source 
is split into two, one that goes into the eye and the other to the reference path. The 
light reflected back from the two paths forms an interference pattern. Due to its 
coherent detection, OCT measures reflecting retinal layers and its thickness. 
Augmentation of these reflecting signals make it able to construct a retinal thickness 
map and to determine the presence of any decrease or increase in thickness.33This 
makes it an important tool in evaluating retinal nerve fibre thickness.34 
 
Visual Evoked Potentials  
The VEP is an important electrophysiological test in the investigation of suspected 
optic nerve disease. Electrical potential differences recorded from the scalp in 
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response to light or pattern stimulation of the eye will be able to detect functional 
loss in the visual pathway from retina to the visual cortex. The VEP is very useful in 
detecting anterior conduction disturbances; but it is not specific with regards to the 
aetiology. 
 
VEPs have been described by Odom et al. (2009)35. They are caused by sensory 
stimulation of the subject’s visual field and are observed using 
electroencephalography. 
 
VEPs are visually evoked electrophysiological signals extracted from the 
electroencephalograhic activity in the visual cortex recorded from the overlying 
scalp. As visual cortex is activated primarily by the central visual field, VEPs depend 
on the functional integrity of central vision at any level of the visual pathway 
including the eye, retina, optic nerve, optic radiations and occipital cortex. 
 
The waveform of a VEP depends on the temporal frequency of the stimulus. At rapid 
rates of stimulation, the waveform becomes approximately sinusoidal and is termed 
‘steady state’. At low temporal frequencies, the waveforms consist of a number of 
discrete deflections and are termed transient VEP. All International Society for 
Clinical Electrophysiology of Vision (ISCEV) standard VEPs are transient. 
 
The standard presents minimum protocols for basic clinical VEP recording. Three 
standard stimulus protocols are defined. The ISCEV standard VEP protocols are 
defined for a single recording channel with a midline occipital active electrode. If 
chiasmal or retrochiasmal disease is suspected, a three-channel montage, using the 
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midline and two lateral electrodes, is recommended in addition to the basic standard 
tests. Following a principle established in earlier standards, ISCEV has selected a 
subset of stimulus and recording conditions, which provides core clinical information 
that can be performed by most clinical electrophysiology laboratories throughout the 
world. These are: 
 
Pattern-reversal VEPs elicited by checkerboard stimuli with large 1_ (60 min of arc) 
and small 0.25_ (15 min) checks. 
Pattern onset/offset VEPs elicited by checkerboard stimuli with large 1_ (60 min of 
arc) and small 0.25_ (15 min) checks. 
Flash VEP elicited by a brief luminance increment, a flash, which subtends a visual 
field of at least 20. 
 
Pattern reversal is the preferred stimulus for most clinical purposes. Pattern-reversal 
VEPs are less variable in waveform and timing then the VEPs elicited by other 
stimuli. The pattern onset/offset is best suited for the detection of malingering and 
for the use in patients with nystagmus. Flash VEP are useful when poor optics, poor 
cooperation or poor vision makes the use of pattern stimulation inappropriate. To 
comply with this standard, at least one standard protocol should be included in every 
clinical VEP recording session so that all laboratories will have a common core of 
information that can be shared or compared.35 
 
ISCEV recognizes that the VEPs may be elicited by a wide range of stimulus 
protocols that are not covered in the standard. Some are widely used in specialised 
VEPs and extended VEP protocols. 
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Manufacturers are encouraged to produce equipment that can perform as many of 
these specialised tests as possible. By limiting these standards to three protocols, the 
intension is that standard VEPs will be incorporated universally into clinical VEP 
testing along with the additional tests and extended protocols that a laboratory may 
choose to use. The standard does not require that all three protocols should be used 
for every investigation on every patient. 
 
VEP pattern reversal checkerboard will be used in conducting this study. The pattern 
reversal VEP consists of a prominent positive component at approximately 100ms 
(P100) preceded and followed by negative components (N75 and N135).  
 
In ethambutol induced optic neuropathy, it is expected to have an abnormal optic 
nerve function, reduction in retinal nerve fiber thickness in OCT of optic nerve head 
and prolonged P100 latency and reduced P100 amplitude in VEP. 
 
2.2 RATIONALE OF THIS STUDY 
In ethambutol toxicity, an accurate detection of toxicity is crucial for the diagnosis. 
Some doctors have reported sudden and irreversible loss of vision in ethambutol 
treated patients. The VEP has been known to be a very useful tool in detecting an 
anterior visual conduction disturbance when there is minimal disturbance in the 
neuro-ophthalmological examinations.21 There have been a few studies on 
tuberculosis patients, where it has been found that VEP and OCT have the ability to 
detect changes which were not detected on routine examination of visual 
function.8,15,21,29-30 These findings confirm the usefulness of VEP and OCT in the 
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detection of subclinical optic nerve disease and suggest their use in routine 
monitoring of ocular function in patients treated with ethambutol. 
 
The aim of this study is to compare the optic nerve function, RNFL thickness using 
OCT and VEP changes prior to starting ethambutol and after 3 months of treatment. 
This study may provide information on retinal nerve fiber thickness using OCT and 
VEP as a potential tool in detecting early changes in ethambutol induced optic 
neuropathy. It can also monitor disease progression in tuberculosis patients treated in 
HUSM. 
 
2.3 OBJECTIVES 
2.3.1 GENERAL OBJECTIVES 
To compare optic nerve functions, RNFL thickness and VEP (P100 latency and 
amplitude) at pre and 3 months post treatment with ethambutol in tuberculosis 
patients. 
 
2.3.2 SPECIFIC OBJECTIVES 
1) To compare optic nerve functions at pre and 3 months post treatment with 
ethambutol in tuberculosis patients. 
 
2)  To compare RNFL thickness at pre and 3 months post treatment with ethambutol 
in tuberculosis patients. 
 
3) To compare VEP changes (P100 Latency and Amplitude) at pre and 3 months 
post treatment with ethambutol in tuberculosis patients.  
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2.3.3 RESEARCH QUESTIONS 
 
1) Is there a significant change in optic nerve functions at pre and 3 months post 
treatment with ethambutol in tuberculosis patients? 
 
2)  Is there a significant change in RNFL thickness at pre and 3 months post 
treatment with ethambutol in tuberculosis patients? 
 
3) Is there a significant change in VEP changes (P100 Latency and Amplitude) at pre 
and 3 months post treatment with ethambutol in tuberculosis patients?  
 
2.3.4 HYPOTHESIS 
There is a significant change in optic nerve functions, RNFL thickness in OCT 
(decrease in thickness) and in VEP (P100 latency and amplitude) at 3 months after 
starting ethambutol in tuberculosis patients. 
 
2.4 METHODOLOGY 
2.4.1 RESEARCH DESIGN 
 Prospective study, one group pre intervention- post intervention design. 
 
2.4.2 STUDY SETTING AND PERIOD 
Venue : Ophthalmology Clinic, HUSM. 
Duration : August 2013- May 2015 
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2.4.3 REFERENCES AND STUDY POPULATION 
Target   : Patients diagnosed with tuberculosis in Malaysia 
Source   : Patients diagnosed with tuberculosis in HUSM 
Sampling frame : Patients diagnosed with tuberculosis in HUSM from August 
2013 until May 2015 that fits into inclusion criteria. Every 
third patient on the list of referred patient is selected. 
 
2.4.4 SAMPLING METHOD 
Simple random sampling is used. Every third patient on the list of referred patient is 
selected. 
 
2.4.5 SELECTION CRITERIA 
2.4.5.1 INCLUSION CRITERIA 
 Patients with pulmonary or extra-pulmonary tuberculosis. 
 Aged above 18 years. 
 Patients on ethambutol containing regime. 
 
2.4.5.2 EXCLUSION CRITERIA 
 Patients with tubercular meningitis. 
 Patients with cerebral tuberculosis. 
 Patients with renal impairment. 
 Patients with past history of anti-tubercular therapy. 
 Mentally challenged patients. 
 Patients with developmental brain disease. 
 Patients with active brain disease. 
19 
 
 Patients who do not consent. 
 Patients below 18 years. 
 Patients with abnormal VEP/RNFL on first time evaluation before treatment. 
 Patients with corneal opacity or presence of dense ocular media opacity. 
 
2.5 SAMPLING AND SAMPLE SIZE 
 
Sample Size Calculations 
To compare optic nerve functions, RNFL thickness and VEP (P100 latency and 
amplitude) at pre and 3 months post treatment with ethambutol in tuberculosis 
patients. 
 
Sample size calculation done by using STATA software for one sample with 
repeated measures. 
 
(VEP latency is more sensitive and accurate than amplitude to detect ethambutol 
toxicity,1,9,15,21,22,31also we did not find any mean for amplitude in the literature 
reviews, so the use of mean and SD latency for sample size calculations.) 
 
P100 Latency 
 sampsi 0 2.5, sd1(5.02) alpha(.05) power(.8) pre(1) post(1) r01(.5) one sample 
 Estimated sample size for one sample with repeated measures 
Assumptions: 
alpha = 0.0500 (two-sided) 
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power = 0.8000 
alternative m = 2.5 ( Jae Keun Chung et al 2012 ) 
sd = 5.02 ( Jae Keun Chung et al 2012 ) 
number of follow-up measurements = 1 
number of baseline measurements = 1 
correlation between baseline & follow-up = 0.500 
Method: CHANGE 
relative efficiency = 1.000 
adjustment to sd = 1.000 
adjusted sd1 = 5.020 
Estimated required sample sizes: 
n1 = 32 
 
(OCT is used to measure the RNFL thickness to detect changes in thickness in 
ethambutol toxicity.29-31) 
 
RNFL Average 
sampsi 0 4.9, sd1(9.8) alpha(.05) power(.8) pre(1) post(1) r01(.5) one sample 
Estimated sample size for one sample with repeated measures 
Assumptions: 
alpha = 0.0500 (two-sided) 
power = 0.8000 
alternative m = 4.9 ( Jae Keun Chung et al 2012 ) 
sd = 9.8 ( Jae Keun Chung et al 2012 ) 
number of follow-up measurements = 1 
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number of baseline measurements = 1 
correlation between baseline & follow-up = 0.500 
Method: CHANGE 
relative efficiency = 1.000 
adjustment to sd = 1.000 
adjusted sd1 = 9.800 
Estimated required sample sizes: 
n1 = 32 
The largest n= 32 
 
We did not find any mean for optic nerve function in the literature reviews, so the use 
of mean and SD latency for sample size calculations were taken according to the 
highest n obtained from available resources. 
 
 Sample size calculation for paired t-test analysis 
 Including dropout + 10% 
 
 n = 32/(1-0.1) = 32/0.9 = 36 patients (72 eyes). Both eyes evaluated as the changes 
may be asymmetrical. 
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2.6 DEFINITION OF TERMS 
 
2.6.1 VEP 
Visual Evoked Potential is the evoked potential or evoked response used to 
determine the visual function of a person or animal. It uses an electrical potential that 
is recorded after presenting a stimulus that stimulates the visual field, which is 
detected by electrophysiological recording methods. Subjects can be stimulated using 
flashing lights or checkerboards that flicker between black on white or white on 
black. 
 
2.6.2 SNELLEN CHART 
A Snellen chart is a chart which is used to measure the visual acuity of a person. It 
was created   by a Dutch ophthalmologist in 1862 named Herman Snellen. The 
Snellen chart is printed with eleven lines of block letters, which progressively 
decrease in size. Visual acuity is measured from 6 meters away and can be performed 
in subjects who cannot identify letters or numbers using the E chart. 
 
2.6.3 SLIT LAMP 
A slit lamp is an instrument consisting of multiple telescope lenses with a high 
intensity light source that is used to view a person’s eye. It can be used to view the 
anterior and posterior segments of the eye. It provides a stereoscopic magnified view 
of all the eye structures in conjunction with other external lens devices. 
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2.6.4 HUMPHREY VISUAL FIELD 
The Humphrey Visual Field is an instrument used to test a subject’s visual field up to 
30 degrees. The subject has to be able to sit up for this test. The patient is set in front 
of a small concave dome in a small machine with a target in the centre and the 
patient is rested on a chin rest and focuses on the centre target. Lights are shone 
inside the dome randomly and the subject will press on a button when he/she sees the 
light. It is used for detection of glaucoma, certain neurological conditions and 
conditions affecting the optic nerve. 
 
2.6.5 ISHIHARA PLATES 
Ishihara colour test plates are used to test colour vision especially for red-green 
colour deficiency. It was created by Dr. Shinobu Ishihara in 1917. This test consists 
of a number of coloured plates which contain a circle of dots that are random in size 
and colour. These patterns of dots form a number or shape clearly visible to subjects 
with normal colour vision but invisible or difficult to see for subjects that have red-
green colour vision defect. There are certain plates that can produce or transform a 
figure that can only be seen by colour deficient individuals.  
 
2.6.6 FUNDUS PHOTOGRAPH 
A fundus photograph is done using a machine made specifically to take a picture of 
the posterior segment of the eye. It is used to keep an accurate record of the optic 
nerve, macula, vessels and vitreous of a subject’s eye. The patient is seated and is 
asked to look directly at the light inside the machine and a photograph is taken. 
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2.6.7 VISUAL ACUITY 
Visual acuity is the measurement of spacial resolution and acuteness or clearness of 
vision. It is tested using charts like the Snellen chart. Normal visual acuity is 6/6 or 
20/20. Visual acuity can be corrected by refraction if it is due to refractive error. It is 
important to have normal ocular and brain function to have normal visual acuity. 
 
2.6.8 COLOUR VISION 
Colour vision is the ability to perceive colours accurately, which is based on the 
wavelength of light. Perception of colours is a subjective process where the brain 
responds to the stimuli that is produced by how light reacts with cone photoreceptors. 
 
2.6.9 VISUAL FIELD 
Visual field is the total object in peripheral vision that can be seen by a subject while 
the subject focuses his/her eye centrally. The visual field test can detect dysfunction 
in central or peripheral vision. It can be tested by comparing the subject’s field of 
vision with the examiner’s or using perimetry. 
 
2.6.10 REFRACTION 
Refraction uses a series of test lenses to measure a subject’s refractive error. 
Refractive error is tested with a patient sitting down while focusing on an object six 
metres away, as an examiner uses a retinoscope to see the reflection in the eye and 
attempts to neutralise the reflection using test lenses. Refractive error is corrected 
using glasses or contact lenses. 
 
